Veracyte Inc (VCYT)
32.84
-0.13
(-0.39%)
USD |
NASDAQ |
Oct 04, 16:00
32.85
+0.01
(+0.03%)
After-Hours: 20:00
Veracyte Research and Development Expense (Annual): 57.30M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 57.30M |
| December 31, 2022 | 40.60M |
| December 31, 2021 | 29.84M |
| December 31, 2020 | 17.20M |
| December 31, 2019 | 14.85M |
| December 31, 2018 | 14.82M |
| December 31, 2017 | 13.88M |
| Date | Value |
|---|---|
| December 31, 2016 | 15.32M |
| December 31, 2015 | 4.984M |
| December 31, 2014 | 4.48M |
| December 31, 2013 | 3.685M |
| December 31, 2012 | 6.608M |
| December 31, 2011 | 6.68M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
14.85M
Minimum
2019
57.30M
Maximum
2023
31.96M
Average
29.84M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Fonar Corp | 1.736M |
| XWELL Inc | -- |
| ProPhase Labs Inc | 1.418M |
| Applied DNA Sciences Inc | 3.735M |
| OncoCyte Corp | 9.294M |